All In Biotech

Drug Trial Radar · NCT07005336

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

A Phase II, Randomized, Multicenter, Open-Label Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 9, 2025

Primary completion

Aug 30, 2026

Study completion Jan 9, 2029

Sponsor

Lead sponsor
TJ Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with sintilimab and chemotherapy versus sintilimab combined with chemotherapy in patients with previously untreated locally advanced unresectable or metastatic NSCLC who are not suitable for targeted therapies such as EGFR or ALK. Eligible subjects will be randomly assigned in a 1:1 ratio to receive either uliledlimab combined with sintilimab and chemotherapy or sintilimab combined with chemotherapy. Enrolled subjects will first enter a safety run-in period. When at least 12 subjects have been randomly assigned to Group A and have received ≥ 1 dose of study drug (with a total of approximately 24 subjects), enrollment will be suspended for safety evaluation. The safety evaluation period will last 3 weeks, during which safety, tolerability, and PK data of uliledlimab combined with sintilimab and chemotherapy will be collected and evaluated by the Safety Review Committee (SRC). The SRC will decide through discussion whether to proceed to the next stage of randomized enrollment, whether additional subjects need to be enrolled for safety evaluation, or whether the study treatment should be terminated due to high safety risks. After the SRC reaches a unanimous resolution, enrollment will continue until a total of approximately 150 subjects are enrolled. All 150 subjects will be included in the final efficacy analysis. If 3 or more subjects experience Grade ≥ 3 treatment-related AEs that are unrelieved and lead to discontinuation of all study drugs during the safety run-in period, enrollment in the next stage will be terminated.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • UliledlimabDrug

    30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,at most 35 cycles

  • SintilimabDrug

    Intravenous infusion at a recommended dose of 200 mg once every 3 weeks,at most 35 cycles

  • PemetrexedDrug

    Intravenously at a recommended dose of 500 mg/m2 body surface area (BSA) ,once every 3 weeks until the disease progresses.

  • GemcitabineDrug

    1000 mg/m2, administered on Days 1 and 8 ,once every 3 weeks (Q3W) for 4 cycles

  • Cisplatin Or CarboplatinDrug

    Cisplatin: 5 mg/m2 administered intravenously every 3-4 weeks for 4 cycles Carboplatin:75 mg/m2, administered intravenously every 3-4 weeks for 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From the date of randomization to the date of first documented disease progression (assessed by a blinded independent central review [BICR] according to RECIST v1.1) or death from any cause, whichever occurs first,assessed up to 6months.

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, China

  • Binzhou Medical University Hospital

    Binzhou, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Chongqing University Three Gorges Hospital

    Chongqing, China

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China

  • Anhui Provincial Cancer Hospital

    Hefei, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Jiangmen Central Hospital

    Jiangmen, China

  • Yunan Cancer Hospital

    Kunming, China

  • Linyi People's Hospital

    Linyi, China

  • Lishui Central Hospital

    Lishui, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Guangxi Medical University Cancer Hospital

    Nanning, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • The Second People's Hospital of Neijiang

    Neijiang, China

  • Shanghai Chest Hospital

    Shanghai, China

  • First Hospital of Shanxi Medical University

    Taiyuan, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

  • Hubei Cancer Hospital

    Wuhan, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • Xiangyang Central Hospital

    Xiangyang, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, China

  • The Second People's Hospital of Yibin

    Yibin, China

  • General Hospital of Ningxia Medical University

    Yinchuan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Zhoukou Central Hospital

    Zhoukou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.